TY - JOUR AU - Bamford, S. AU - Dawson, E. AU - Forbes, S. PY - 2004 DA - 2004// TI - The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website JO - Br J Cancer VL - 91 ID - Bamford2004 ER - TY - JOUR AU - Etienne-Grimaldi, M. C. AU - Formento, J. L. AU - Francoual, M. PY - 2008 DA - 2008// TI - KRAS mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4906 DO - 10.1158/1078-0432.CCR-07-4906 ID - Etienne-Grimaldi2008 ER - TY - JOUR AU - Andreyev, H. J. AU - Norman, A. R. AU - Cunningham, D. PY - 1998 DA - 1998// TI - RAS mutations in patients with colorectal cancer: the multicenter "RASCAL" study JO - J Natl Cancer Inst VL - 90 UR - https://doi.org/10.1093/jnci/90.9.675 DO - 10.1093/jnci/90.9.675 ID - Andreyev1998 ER - TY - JOUR AU - Maughan, T. S. AU - Adams, R. A. AU - Smith, C. G. PY - 2011 DA - 2011// TI - Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial JO - Lancet VL - 377 UR - https://doi.org/10.1016/S0140-6736(11)60613-2 DO - 10.1016/S0140-6736(11)60613-2 ID - Maughan2011 ER - TY - JOUR AU - Bokemeyer, C. AU - Bondarenko, I. AU - Makhson, A. PY - 2009 DA - 2009// TI - Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.8397 DO - 10.1200/JCO.2008.20.8397 ID - Bokemeyer2009 ER - TY - CHAP AU - Punt, C. J. AU - Tol, J. AU - Rodenburg, C. J. PY - 2008 DA - 2008// TI - Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) BT - J Clin Oncol ID - Punt2008 ER - TY - JOUR AU - Richman, S. D. AU - Seymour, M. T. AU - Chambers, P. PY - 2009 DA - 2009// TI - KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial JO - JCO Dec VL - 10 UR - https://doi.org/10.1200/JCO.2009.22.4295 DO - 10.1200/JCO.2009.22.4295 ID - Richman2009 ER - TY - JOUR AU - Amado, R. G. AU - Wolf, M. AU - Peeters, M. PY - 2008 DA - 2008// TI - Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.7116 DO - 10.1200/JCO.2007.14.7116 ID - Amado2008 ER - TY - JOUR AU - Lièvre, A. AU - Bachet, J. B. AU - Boige, V. PY - 2008 DA - 2008// TI - KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.5906 DO - 10.1200/JCO.2007.12.5906 ID - Lièvre2008 ER - TY - JOUR AU - Van Cutsem, E. AU - Köhne, C. H. AU - Hitre, E. PY - 2009 DA - 2009// TI - Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0805019 DO - 10.1056/NEJMoa0805019 ID - Van Cutsem2009 ER - TY - STD TI - Tveit K, Guren T, Glimelius B, et al: Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab. as first-line treatment of metastatic colorectal cancer: The NORDIC VII Study (NCT00145314). . 2010, ESMO: # LBA20- ID - ref11 ER - TY - JOUR AU - De Roock, W. AU - Claes, B. AU - Bernascon, D. PY - 2011 DA - 2011// TI - Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(10)70209-6 DO - 10.1016/S1470-2045(10)70209-6 ID - De Roock2011 ER - TY - CHAP AU - Tejpar, S. AU - Bokemeyer, C. AU - Celik, I. PY - 2011 DA - 2011// TI - Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab BT - J Clin Oncol ID - Tejpar2011 ER - TY - JOUR AU - Porschen, R. AU - Arkenau, H. T. AU - Kubicka, S. PY - 2007 DA - 2007// TI - AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.2684 DO - 10.1200/JCO.2006.09.2684 ID - Porschen2007 ER - TY - JOUR AU - Bazan, V. AU - Migliavacca, M. AU - Zanna, I. PY - 2002 DA - 2002// TI - Specific codon 13 KRAS mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 KRAS mutations are associated with mucinous histotype JO - Ann Oncol VL - 13 UR - https://doi.org/10.1093/annonc/mdf226 DO - 10.1093/annonc/mdf226 ID - Bazan2002 ER - TY - CHAP AU - Zhang, W. AU - El-Khoueiry, A. AU - Yang, D. PY - 2009 DA - 2009// BT - KRAS mutation status associated with clinical outcome in metastatic colorectal cancer patients treated with 5-fluorouracil/oxaliplatin ID - Zhang2009 ER - TY - JOUR AU - Moosmann, N. AU - Fischer von Weikersthal, L. AU - Vehling-Kaiser, U. PY - 2011 DA - 2011// TI - Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With MetastaticColorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.31.1936 DO - 10.1200/JCO.2010.31.1936 ID - Moosmann2011 ER - TY - JOUR AU - Ince, W. L. AU - Jubb, A. M. AU - Holden, S. N. PY - 2005 DA - 2005// TI - Association of KRAS, b-raf, and p53 status with the treatment effect of bevacizumab JO - J Natl Cancer Inst VL - 97 UR - https://doi.org/10.1093/jnci/dji174 DO - 10.1093/jnci/dji174 ID - Ince2005 ER - TY - JOUR AU - Ocvirk, J. AU - Brodowicz, T. AU - Wrba, F. PY - 2010 DA - 2010// TI - Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial JO - World J Gastroenterol VL - 16 UR - https://doi.org/10.3748/wjg.v16.i25.3133 DO - 10.3748/wjg.v16.i25.3133 ID - Ocvirk2010 ER - TY - BOOK AU - Reinacher-Schick, A. AU - Arnold, D. AU - Kubicka, S. PY - 2010 DA - 2010// TI - Impact of KRAS status on survival in patients (pts.) with metastatic colorectal cancer (MCRC) undergoing Bevacizumab (BEV) containing chemotherapy regimen – Analysis of the AIO Colorectal Cancer Study Group ID - Reinacher-Schick2010 ER - TY - JOUR AU - Stinchcombe, T. E. AU - Der, C. J. PY - 2011 DA - 2011// TI - Are all KRAS mutations created equal? JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70200-5 DO - 10.1016/S1470-2045(11)70200-5 ID - Stinchcombe2011 ER - TY - JOUR AU - Arkenau, H. T. AU - Arnold, D. AU - Cassidy, J. PY - 2008 DA - 2008// TI - Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.7759 DO - 10.1200/JCO.2008.16.7759 ID - Arkenau2008 ER - TY - CHAP AU - Lenz, H. J. AU - Zhang, W. AU - Shi, M. M. PY - 2008 DA - 2008// TI - ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2 BT - J Clin Oncol ID - Lenz2008 ER - TY - JOUR AU - Friboulet, L. AU - Barrios-Gonzales, D. AU - Commo, F. PY - 2011 DA - 2011// TI - Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-0790 DO - 10.1158/1078-0432.CCR-11-0790 ID - Friboulet2011 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/349/prepub UR - http://www.biomedcentral.com/1471-2407/12/349/prepub ID - ref25 ER -